Author

A. Noronha

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Y. Yarden· 2 shared A. H. C. van Kampen· 1 shared A. Tennenhouse· 1 shared C. Wilds· 1 shared D. Fass· 1 shared E. Makowski· 1 shared E. Sofyali· 1 shared G. Kozlov· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Y. Yarden

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhanced binding of guanylated poly(A) RNA by the LaM domain of LARP1

G. Kozlov, J. Jiang, T. Rutherford, A. Noronha, C. Wilds, K. Gehring

This study investigates LARP1's preference for singly guanylated poly(A) RNA sequences and shows cyclic di-nucleotides bind with sub-micromolar affinity.

bioRxiv · May 8, 2024Biochemistry

Reliable energy-based antibody humanization and stabilization

A. Tennenhouse, L. Khmelnitsky, R. Khalaila, N. Yeshaya, A. Noronha, M. Lindzen, E. Makowski, I. Zaretsky, Y. Fridmann Sirkis, Y. Galon-Wolfenson, P. M. Tessier, J. Abramson, Y. Yarden, D. Fass, S. J. Fleishman

The paper introduces CUMAb, a computational method for humanizing antibodies that improves stability and binding by systematically grafting CDRs onto human frameworks and ranking designs using Rosetta simulations.

bioRxiv · Aug 14, 2022Bioengineering

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer

S. Borgoni, E. Sofyali, M. Soleimani Dodaran, H. Wilhelm, K. Mueller-Decker, R. Will, A. Noronha, P. J. Verschure, Y. Yarden, L. Magnani, A. H. C. van Kampen, P. D. Moerland, S. Wiemann

This study identifies ATF3 as a novel mediator of endocrine resistance in breast cancer through time-resolved profiling and validates its role in key signaling pathways and clinical relevance.

bioRxiv · Jun 8, 2020Cancer Biology